| Literature DB >> 27817168 |
Jianguo Chen1, Chaoyan Shen2, Jinlong Shi1, Jianhong Shen1, Wenjuan Chen2, Jie Sun2, Shaocheng Fan1, Yuanqi Bei2, Peng Xu3, Hao Chang4, Rui Jiang1, Lu Hua2, Bin Ji5, Qingfeng Huang6.
Abstract
DIX domain containing 1 (DIXDC1), the human homolog of coiled-coil-DIX1 (Ccd1), is a positive regulator of Wnt signaling pathway. Recently, it was found to act as a candidate oncogene in colon cancer, non-small-cell lung cancer, and gastric cancer. In this study, we aimed to investigate the clinical significance of DIXDC1 expression in human glioma and its biological function in glioma cells. Western blot and immunohistochemistry analysis showed that DIXDC1 was overexpressed in glioma tissues and glioma cell lines. The expression level of DIXDC1 was evidently linked to glioma pathological grade and Ki-67 expression. Kaplan-Meier curve showed that high expression of DIXDC1 may lead to poor outcome of glioma patients. Serum starvation and refeeding assay indicated that the expression of DIXDC1 was associated with cell cycle. To determine whether DIXDC1 could regulate the proliferation and migration of glioma cells, we transfected glioma cells with interfering RNA-targeting DIXDC1; investigated cell proliferation with Cell Counting Kit (CCK)-8, flow cytometry assays, and colony formation analyses; and investigated cell migration with wound healing assays and transwell assays. According to our data, knockdown of DIXDC1 significantly inhibited proliferation and migration of glioma cells. These data implied that DIXDC1 might participate in the development of glioma, suggesting that DIXDC1 can become a potential therapeutic strategy for glioma.Entities:
Keywords: DIXDC1; Glioma; Migration; Prognosis; Proliferation
Mesh：
Substances：
Year: 2016 PMID： 27817168 DOI： 10.1007/s10571-016-0433-5
Source DB: PubMed Journal: Cell Mol Neurobiol ISSN： 0272-4340 Impact factor: 5.046